SWOG clinical trial number
CTSU/E2607
A Phase II Trial of Dasatinib in KIT-Positive Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas
Closed
Phase
Published
Abbreviated Title
Ph II trial of dasatinib in KIT + patients with unresectable locally adv or Stage IV mucosal, acral and vulvovaginal melanomas
Status Notes
This study will permanently close to accrual effective 12/29/15.
Activated
12/01/2011
Participants
CTSU
Research committees
Melanoma
Treatment
Dasatinib
Eligibility Criteria Expand/Collapse
SWOG has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://ctsu.org/) for more information and registration procedures.
Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://ctsu.org/) for more information and registration procedures.
Publication Information Expand/Collapse
2017
Other Clinical Trials
SWOG Clinical Trial Number
S2000
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases
Research Committee(s)
Melanoma
Activated
09/23/2020
Accrual
100%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6174
A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Research Committee(s)
Melanoma
Activated
10/01/2018
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6141
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Research Committee(s)
Melanoma
Activated
09/10/2015
Open
Phase